dr. cohen on the value of pfs as an endpoint in head and neck cancer
Published 5 years ago • 111 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
0:58
dr. wright on pfs as an endpoint in ovarian cancer trials
-
2:05
dr. cohen discusses head and neck cancer pathways
-
0:59
dr. thigpen on pfs as an endpoint in ovarian cancer trials
-
32:36
cancer immunotherapy clinical trials with dr. ezra cohen
-
0:58
dr. cohen on the evolution of surgery in ovarian cancer
-
3:59
os vs pfs with olaratumab
-
5:56
patient selection in treating hnscc
-
28:11
immunotherapy - health matters
-
2:21
challenging overall survival as an endpoint in ovarian cancer
-
8:58
improving the analyses of progression-free survival from clinical trials for novel cancer treatments
-
4:11
head and neck cancer clinical trials | what are the benefits?
-
2:06
dr. cohen discusses surgery in early stage ovarian cancer
-
10:30
overall vs. progression-free survival, response rates: oncology terminology 101 (by oster oncology)
-
2:16
what are progression free survival (pfs) and overall survival (os)?
-
1:27
where to go next with pembrolizumab and other anti-pd-1 therapies in head and neck cancer
-
3:39
valuable endpoints beyond os in ovarian cancer
-
11:19
new endpoints in clinical trials to better serve patients
-
1:43
one stop shopping: dr. eudocia lee | dana-farber cancer institute
-
5:07
clifford a. hudis, md: the value of progression-free survival (pfs)